A comparison of the antianhedonic effects of repeated ketamine infusions in melancholic and non-melancholic depression

Objectives Melancholic depression may respond differently to certain treatments. The aim of this study was to compare the antianhedonic effects of six intravenous injections of 0.5 mg/kg ketamine in patients with melancholic and non-melancholic depression, which remain largely unknown. Methods Individuals experiencing melancholic (n = 30) and non-melancholic (n = 105) depression were recruited and assessed for anhedonic symptoms using the Montgomery–Åsberg Depression Rating Scale (MADRS). The presence of melancholic depression was measured with the depression scale items at baseline based on DSM-5 criteria. Results A total of 30 (22.2%) patients with depression fulfilled the DSM-5 criteria for melancholic depression. Patients with melancholic depression had a non-significant lower antianhedonic response (43.3 vs. 50.5%, t = 0.5, p > 0.05) and remission (20.0 vs. 21.0%, t = 0.01, p > 0.05) to repeated-dose ketamine infusions than those with non-melancholic depression. The melancholic group had significantly lower MADRS anhedonia subscale scores than the non-melancholic group at day 26 (p < 0.05). Conclusion After six ketamine infusions, the improvement of anhedonic symptoms was found in both patients with melancholic and non-melancholic depression, and the efficacy was similar in both groups.

[1]  Y. Ning,et al.  Gender differences in the antianhedonic effects of repeated ketamine infusions in patients with depression , 2022, Frontiers in Psychiatry.

[2]  Y. Ning,et al.  Antianhedonic effects of serial intravenous subanaesthetic ketamine in anxious versus nonanxious depression. , 2022, Journal of affective disorders.

[3]  Y. Ning,et al.  Association of VEGF With Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Treatment-Refractory Depression , 2021, Frontiers in Psychiatry.

[4]  Y. Ning,et al.  Comparative effectiveness of repeated ketamine infusions in treating anhedonia in bipolar and unipolar depression. , 2021, Journal of affective disorders.

[5]  D. Martino,et al.  Neurocognitive performance in melancholic and non-melancholic major depressive disorder: A meta-analysis of comparative studies , 2021, Psychiatry Research.

[6]  Nelson B Rodrigues,et al.  The effect of repeated doses of intravenous ketamine on measures of workplace attendance and productivity in adults with major depressive and bipolar disorder: Results from the canadian rapid treatment center of excellence , 2021, Psychiatry Research.

[7]  A. Serretti,et al.  Melancholic features in major depression – a European multicenter study , 2021, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[8]  R. McIntyre,et al.  Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder , 2021, Neuropsychiatric disease and treatment.

[9]  L. Balbuena,et al.  Melancholic depression and response to quetiapine: A pooled analysis of four randomized placebo-controlled trials. , 2020, Journal of affective disorders.

[10]  R. Baldessarini,et al.  Antidepressant responses in direct comparisons of melancholic and non-melancholic depression , 2020, Journal of psychopharmacology.

[11]  Nelson B Rodrigues,et al.  Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence. , 2020, Journal of affective disorders.

[12]  E. Ballard,et al.  The effects of ketamine on typical and atypical depressive symptoms , 2020, Acta psychiatrica Scandinavica.

[13]  H. Kautiainen,et al.  Relationship of non-melancholic and melancholic depressive symptoms with all-cause mortality: A prospective study in a primary care population. , 2020, Journal of psychosomatic research.

[14]  Z. Segal,et al.  The symptom‐specific efficacy of antidepressant medication vs. cognitive behavioral therapy in the treatment of depression: results from an individual patient data meta‐analysis , 2019, World psychiatry : official journal of the World Psychiatric Association.

[15]  Meng Li,et al.  A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation. , 2019, Journal of affective disorders.

[16]  R. McIntyre,et al.  The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder , 2019, Front. Psychiatry.

[17]  Y. Ning,et al.  Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression. , 2018, Journal of psychiatric research.

[18]  D. Martino,et al.  Differential response to lithium between melancholic and non-melancholic unipolar depression , 2018, Psychiatry Research.

[19]  M. Manchia,et al.  Clinical and biological predictors of response to electroconvulsive therapy (ECT): a review , 2016, Neuroscience Letters.

[20]  C. Correll,et al.  Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study , 2015, Psychological Medicine.

[21]  J. Roiser,et al.  Neural correlates of change in major depressive disorder anhedonia following open-label ketamine , 2015, Journal of psychopharmacology.

[22]  J. Roiser,et al.  Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression , 2014, Translational Psychiatry.

[23]  G. Parker,et al.  Biological differences between melancholic and nonmelancholic depression subtyped by the CORE measure , 2014, Neuropsychiatric disease and treatment.

[24]  M. Kuskowski,et al.  Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. , 2014, Journal of affective disorders.

[25]  Dennis S. Charney,et al.  Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression , 2013, Biological Psychiatry.

[26]  Wen-hua Liu,et al.  Clinical utility of the Snaith-Hamilton-Pleasure scale in the Chinese settings , 2012, BMC Psychiatry.

[27]  R. Shelton,et al.  Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. , 2011, Journal of affective disorders.

[28]  王瑛,et al.  Reliability, validity and sensitivity of Montgomery-Asberg depression rating scale for patients with current major depression disorder , 2011 .

[29]  H. Takagi,et al.  A meta-analysis of comparative studies of endovascular versus open repair for blunt thoracic aortic injury. , 2008, The Journal of thoracic and cardiovascular surgery.

[30]  Peter Muris,et al.  The assessment of anhedonia in clinical and non-clinical populations: further validation of the Snaith-Hamilton Pleasure Scale (SHAPS). , 2007, Journal of affective disorders.

[31]  P. Sullivan,et al.  Melancholia: Definitions, Risk Factors, Personality, Neuroendocrine Markers and Differential Antidepressant Response , 2001, The Australian and New Zealand journal of psychiatry.

[32]  M. Hamilton,et al.  A Scale for the Assessment of Hedonic Tone the Snaith–Hamilton Pleasure Scale , 1995, British Journal of Psychiatry.

[33]  I. Hickie,et al.  Defining Melancholia: Properties of a Refined Sign-Based Measure , 1994, British Journal of Psychiatry.

[34]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[35]  Robert C. Wolpert,et al.  A Review of the , 1985 .